Toward personalized therapy in AML: In vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML

K. M. Bernot, R. F. Siebenaler, S. P. Whitman, N. A. Zorko, G. G. Marcucci, R. Santhanam, E. H. Ahmed, M. Ngangana, K. K. McConnell, J. S. Nemer, D. L. Brook, S. K. Kulp, C. S. Chen, D. Frankhouser, P. Yan, R. Bundschuh, X. Zhang, A. M. Dorrance, K. E. Dickerson, D. JarjouraW. Blum, G. Marcucci, M. A. Caligiuri

Research output: Contribution to journalLetterpeer-review

12 Scopus citations
Original languageEnglish (US)
Pages (from-to)2379-2382
Number of pages4
Issue number12
StatePublished - Dec 2013
Externally publishedYes

Bibliographical note

Funding Information:
We thank The Ohio State University Comprehensive Cancer Center’s Shared Resources: Biostatistics, Nucleic Acid, Comparative Pathology and Mouse Phenotyping and Analytical Cytometry. This work was supported in part by National Cancer Institute, Bethesda, MD, USA, grants: to MAC (CA089341; CA009338), to GM (CA102031), to MAC and GM (CA140158), to NAZ (T32 GM12453), and to KMB (T32 CA009338). We also thank the Thomas J. Bardos Science Education Award (RFS), the American Society of Hematology Trainee Research Award (RFS), the OSU College of Medicine Fellowship (NAZ), Pelotonia Fellowships (NAZ, RFS, and AMD), Wells Family Fellowship (JSN and DLB) and the American Society of Hematology Minority Medical Student Award Program (MN).

Cite this